Radiology Journals
Radiology
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?


Article ID

Home
General Radiology
Messages
Conferences
Jobs
Newsletters
My Library
Topics in
Radiology
        Angiography
        Basic Science
        CT/SPECT/PET
        Chest
        Economics of Medicine
        Gastrointestinal
        Interventional
        MRI
        Mammography
        Musculoskeletal
        Neuroradiology
        Nuclear Medicine
        PACS/ General
        Pediatric Radiology
        Popular Press
        Radiotherapy (XRT)
        Ultrasound
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
 
Sponsor
MDLinx Email Article

To email this article, enter your own "From Email" address,
the recipient's "To Email" address, and click the "Send Email" button.
You may send to up to 5 email addresses.
*From Email:  
*To Email:  
To Email:  
To Email:  
To Email:  
To Email:  
Dose-per-fraction escalation of accelerated hypofractionated three-dimensional conformal radiotherapy in locally advanced non-small cell lung cancer
Kepka L et al. - In a trial to determine the efficacy of accelerated hypofractionated 3-dimensional conformal radiotherapy (3D-CRT) with dose-per-fraction escalation for treatment of stage III non-small cell lung cancer (NSCLC), it appears that although dose escalation with accelerated hypofractionated 3D-CRT was limited, results and toxicity profiles obtained using this technique are promising.

Methods
  • 173 pts with stage III NSCLC were treated using accelerated 3D-CRT and the simultaneous boost technique.
  • The total dose of 56.7 Gy (including 39.9 Gy to elective area) was delivered over 4 wks in fractions of 2.7 Gy (1.9 Gy to elective area).
  • Dose-per-fraction escalation study commenced after the outcomes of 70 pts had been evaluated.
  • Dose per fraction was increased from 2.7 through 2.8 Gy (level 1 escalation) to 2.9 Gy (level 2 escalation); total dose increased, respectively, from 56.7 Gy through 58.8 Gy to 60.9 Gy.
  • Dose to the elective area and overall treatment time remained unchanged.
  • Fit pts received 2 to 3 courses of chemotherapy before radiotherapy.

Results
  • 2- and 3-yr overall survival rates were 32% and 19%, respectively.
  • Of the pts, 7% had grade III acute esophageal toxicity and 6% had grade III or greater late pulmonary toxicity.
  • 2 of 9 pts who received level 2 escalation (60.9 Gy) died of pulmonary toxicity.
  • The study was terminated at a dose of 58.8 Gy; this schema was adopted as institutional policy for treatment of stage III NSCLC.
[more...]
Sponsor

Read a Different Specialty

General Radiology Articles
Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pain
Pediatrics
Practice Management
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Profession Index

General Radiology Articles
Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
Sponsor
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2009 MDLinx, Inc.